Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial.
Beckendorf V, Guerif S, Le Prisé E, Cosset JM, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud JM, Maingon P, Hannoun-Levi JM, Malissard L, Simon JM, Pommier P, Hay M, Dubray B, Lagrange JL, Luporsi E, Bey P. Beckendorf V, et al. Among authors: dubray b. Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1056-63. doi: 10.1016/j.ijrobp.2010.03.049. Epub 2010 Dec 14. Int J Radiat Oncol Biol Phys. 2011. PMID: 21147514 Clinical Trial.
Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer.
Vaz SC, Adam JA, Delgado Bolton RC, Vera P, van Elmpt W, Herrmann K, Hicks RJ, Lievens Y, Santos A, Schöder H, Dubray B, Visvikis D, Troost EGC, de Geus-Oei LF. Vaz SC, et al. Among authors: dubray b. Radiother Oncol. 2022 Mar;168:37-39. doi: 10.1016/j.radonc.2021.12.048. Epub 2022 Jan 20. Radiother Oncol. 2022. PMID: 35066001 Free PMC article. Review.
The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity.
Beckendorf V, Guérif S, Le Prisé E, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bachaud JM, Maingon P, Lagrange JL, Malissard L, Simon JM, Pommier P, Hay MH, Dubray B, Luporsi E, Bey P. Beckendorf V, et al. Among authors: dubray b. Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1056-65. doi: 10.1016/j.ijrobp.2004.05.033. Int J Radiat Oncol Biol Phys. 2004. PMID: 15519775 Clinical Trial.
HDR versus LDR gynecological brachytherapy revisited.
Scalliet P, Gerbaulet A, Dubray B. Scalliet P, et al. Among authors: dubray b. Radiother Oncol. 1993 Aug;28(2):118-26. doi: 10.1016/0167-8140(93)90003-q. Radiother Oncol. 1993. PMID: 8248552 Review.
[Preliminary results of the assessment of intensity modulated radiotherapy (IMRT) for prostatic and head and neck tumors (STIC 2001)].
Marchal C, Lapeyre M, Beckendorf V, Aletti P, Haslé E, Dubois JB, Maingon P, Bensadoun RJ, Le Prise E, Lartigau E, Carrie C, Dubray B, Marchesi V, Ailleres N, Naudy S, Marcie S, Manens JP, Mazurier J, Ginestet C, Chauvin F, Pommier P, Gerard JP, Carrere MO. Marchal C, et al. Among authors: dubray b. Cancer Radiother. 2004 Nov;8 Suppl 1:S121-7. Cancer Radiother. 2004. PMID: 15679257 French.
Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P, Bohn P, Edet-Sanson A, Salles A, Hapdey S, Gardin I, Ménard JF, Modzelewski R, Thiberville L, Dubray B. Vera P, et al. Among authors: dubray b. Radiother Oncol. 2011 Jan;98(1):109-16. doi: 10.1016/j.radonc.2010.10.011. Epub 2010 Nov 4. Radiother Oncol. 2011. PMID: 21056487
143 results